Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.090
-0.010 (-0.24%)
At close: Apr 28, 2026, 4:00 PM EDT
4.080
-0.010 (-0.24%)
After-hours: Apr 28, 2026, 5:20 PM EDT
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Aquestive Therapeutics stock have an average target of 9.00, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 120.05% from the current stock price of 4.09.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $5 → $8 | Buy | Maintains | $5 → $8 | +95.60% | Nov 7, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $9 → $12 | Buy | Maintains | $9 → $12 | +193.40% | Oct 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +95.60% | Sep 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +144.50% | Jun 17, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $15 → $7 | Buy | Initiates | $15 → $7 | +71.15% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
49.03M
from 44.55M
Increased by 10.08%
Revenue Next Year
73.35M
from 49.03M
Increased by 49.60%
EPS This Year
-0.49
from -0.78
EPS Next Year
-0.43
from -0.49
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 53.0M | 117.6M | ||||||
| Avg | 49.0M | 73.4M | ||||||
| Low | 44.8M | 51.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 19.0% | 139.8% | ||||||
| Avg | 10.1% | 49.6% | ||||||
| Low | 0.5% | 4.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | -0.40 | -0.07 | ||
| Avg | -0.49 | -0.43 | ||
| Low | -0.56 | -0.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.